Filing Flows › Aurinia Pharmaceuticals (AUPH) › Q3 2025
Aurinia Pharmaceuticals (AUPH) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Aurinia Pharmaceuticals (AUPH) reported revenue of $73.5M for the third quarter 2025 (Q3 2025), +8% from a year earlier and +5% from the quarter before. Operating margin was 40.5%, net earnings $31.6M (42.9% of revenue).
Aurinia Pharmaceuticals, Q3 2025: revenue $73.5M (+8% year over year), operating margin 40.5%, net earnings $31.6M, operating cash flow $44.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $73.5M | +5% | +8% |
| Operating profit | $29.7M | +48% | +153% |
| Net earnings | $31.6M | +47% | +120% |
| Operating cash flow | $44.4M | +0.5% | +161% |
What changed
Revenue was $73.5M in Q3 2025, up 8% year over year and up 5% from the previous quarter. Net product sales was the largest line at 96% of revenue. Net product sales added $15.1M year over year (up 27%), 265% of the total change. License, collaboration and royalty revenue declined 77%.
Operating profit was $29.7M, a 40.5% margin (up 23.2 points year over year). Of the extra revenue versus a year earlier, 316% reached operating profit, above the 17% margin then. Total costs fell 22% while revenue rose 8%. The fastest-growing cost line was Research & development (+177%). Net earnings were $31.6M, up 120% year over year. The effective tax rate was 1.3%.
Operating cash flow was $44.4M (up 161% year over year), 141% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $5.9M of share-based compensation.
Questions
What was Aurinia Pharmaceuticals' revenue in the third quarter 2025?
Aurinia Pharmaceuticals (AUPH) reported revenue of $73.5M for the third quarter 2025 (Q3 2025), +8% from a year earlier and +5% from the quarter before.
Was Aurinia Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $29.7M (40.5% of revenue) and net earnings $31.6M.